Sharma A, Bhatt NS, St Martin A, et al. - The traits and outcomes of hematopoietic stem-cell transplantation (HSCT) recipients after developing COVID-19 are described in this study. In response to the pandemic, a special form for COVID-19-related data capture was implemented by the Center for International Blood and Marrow Transplant Research (CIBMTR) on March 27, 2020. The analysis was performed including all patients—irrespective of age, diagnosis, donor type, graft source, or conditioning regimens—with data cutoff of August 12, 2020. The CIBMTR included 318 HSCT recipients diagnosed with COVID-19. For allogeneic HSCT recipients and autologous HSCT recipients, the median time from HSCT to COVID-19 diagnosis was 17 months (IQR 8–46) and 23 months (8–51), respectively. Disease severity was mild in 49% of patients, while severe disease requiring mechanical ventilation occurred in 14% of 318 patients. Findings revealed poor overall survival for recipients of autologous and allogeneic HSCT who develop COVID-19. An overall survival of 68% for recipients of allogeneic HSCT and 67% (55–78) for recipients of autologous HSCT was reported at 30 days after COVID-19 diagnosis. A higher risk of mortality was observed in correlation with age 50 years or older, male gender, and development of COVID-19 within 12 months of transplantation among allogeneic HSCT recipients, and in correlation with a disease indication of lymphoma compared with plasma cell disorder or myeloma in autologous HSCT recipients. These findings highlight the necessity for stringent surveillance and aggressive treatment measures in HSCT recipients who develop COVID-19.